Trial Profile
Single center, open label, phase I study of intracranial injection of NK-92/5.28.z cells in patients with recurrent HER2-positive glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs HER2 taNK (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; First in man; Pharmacodynamics
- Acronyms CAR2BRAIN
- 26 Mar 2024 Planned End Date changed from 31 Dec 2023 to 30 Jun 2026.
- 26 Mar 2024 Planned primary completion date changed from 31 Oct 2023 to 31 Dec 2025.
- 26 Mar 2024 Status changed from recruiting to active, no longer recruiting.